Axsome Therapeutics (AXSM) Shares Outstanding (Diluted Average) (2020 - 2026)

Axsome Therapeutics has disclosed Shares Outstanding (Diluted Average) across 7 years of filings, most recently posting $51.2 million for Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $51.2 million, up 4.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $51.2 million (up 4.76% YoY), and the FY2025 annual result was $49.7 million, up 3.83% from the prior year.
• Shares Outstanding (Diluted Average) came in at $51.2 million for Q1 2026 at Axsome Therapeutics, up from $49.7 million in the prior quarter.
• In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $51.2 million in Q1 2026 to a low of $38.3 million in Q1 2022.
• The 5-year median for Shares Outstanding (Diluted Average) is $47.4 million (2024), against an average of $45.8 million.
• Across the five-year window, Shares Outstanding (Diluted Average) grew 13.57% in 2023 and increased 1.24% in 2024, its largest moves.
• Axsome Therapeutics' Shares Outstanding (Diluted Average) stood at $40.7 million in 2022, then rose by 11.73% to $45.4 million in 2023, then advanced by 5.48% to $47.9 million in 2024, then grew by 3.83% to $49.7 million in 2025, then advanced by 2.92% to $51.2 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $51.2 million (Q1 2026), $49.7 million (Q4 2025), and $50.0 million (Q3 2025), per Business Quant data.